INTRODUCTION
============

According to the USDA National Nutrient Database, 28 g of almonds contain 6 g of protein \[12% of daily value (DV)\], 12.44 g of unsaturated fat (88% of DV), 3.5 g of dietary fiber (14% of DV), and 7.27 g of vitamin E (36% of DV) \[[@B1]\]. Almonds are also known as an anti-oxidative and anti-inflammatory food that contains polyphenolic compounds including flavonoids and proanthocyanidins \[[@B2][@B3]\]. There have been various studies which examined the health benefits of almond intake in the fields of weight management, heart health, and diabetes. One of major results from the previous almonds studies might be improvement of blood lipid profiles, including the levels of triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol particularly among subjects with diet-related clinical symptoms such as obesity, diabetes, and hyperlipidemia \[[@B4][@B5][@B6]\]. Even with these positive effects of almond intake, there have been continuous arguments whether regular consumption of almonds may increase the body weight or not due to fairly high calories like other nuts. However, previous studies have reported that almonds have no effect on weight changes in both healthy subjects who consumed 68 g of almonds \[[@B7]\] and hyperlipidemic subjects who consumed 73 g of almonds \[[@B8]\]. Even in the study consuming almonds over six months, subjects\' body weight were not increased \[[@B9]\]. Daily almond intake might also help changing the body composition as reported in a weight reduction program study \[[@B10]\]. In this previous study, participants consuming 56 g of almonds per day decreased waist circumference by 14%, while a highly controlled carbohydrate diet decreased waist circumference by 9% (*P* \< 0.05).

Another 10-weeks long study conducted by Hollis and Mattes found that the subjects in almond treatment groups showed similar energy intake compared to control group who followed their usual diet. According to the authors, the results suggest that almond intervention as a replacement for other food did not change overall calorie intakes. Authors stated that these compensations were caused by the fiber and protein in almonds, which both increase satiation \[[@B11]\]. Recent 5-arm randomized parallel study conducted by Tan and Mattes examined significant reductions in the daylong hunger ratings among the subjects who consumed 43 g of almonds as a morning or afternoon snack compared to the subjects who consumed same amount of almonds with breakfast or lunch. Authors stated that the results indicate potential different effects of almond intake based on the timing of consumption during a day \[[@B12]\].

These previous results led us to investigate the effects of daily almond consumption based on the different timing of almond intake during a day (as a preload versus as a snack between meals) compared with iso-caloric food among the free-living adults with no clinical symptoms. The current study is particularly focused on the changes of body composition using bioimpedance analyzer, lipid profiles, and oxidative and inflammation indicators with serial measurement during 16 weeks of almond intake.

SUBJECTS AND METHODS
====================

Subjects
--------

Participants were recruited through flyers and newspaper advertisements in Seoul, South Korea. Subjects were first screened using detailed and general medical questionnaires and trained nurse interviewed each subject for enrollment. Subjects were selected if they were non-smokers aged 20--39. Other inclusion criteria included a body mass index (BMI) of 17--30 kg/m^2^ and a habitual diet close to that of a typical Korean diet. Subjects were excluded if they had any previous hypertension, arteriosclerosis, or metabolic diseases, had experienced any significant weight change in the last six months, were chronically ill or taking medications, consumed nuts frequently (more than twice per week), had erratic exercise habits, were smokers, or consumed alcohol more than twice per week. Women who had an irregular menstrual cycle, took birth control pills, or were pregnant or lactating were also excluded. This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Ethics Committee of Sookmyung Women\'s University, Seoul, Korea (SMWU-1407-BR-006). Written informed consent was obtained from all study subjects.

Study design
------------

This study was a randomized, 3-arms parallel, controlled 16-week trial. After being screened, eligible participants were simply randomized without any restriction into one of the three study arms using a computerized random number generator by the primary investigator. (1) In the pre-meal group (PM), participants were instructed to consume 56 g of almonds per day as a preload when having regular meals. They were directed to prepare the table first and consume nearly 1/3 amount of almond before each meal. (2) In the snack group (SN), participants were instructed to consume 56 g of almonds between meals as snacks. A snack was defined as an eating event that occurred between participants\' regular meals, specifically two hours before and after meals. All the participants in the PM and SN groups were provided daily portions of packaged almonds. (3) In the control group (CL), participants were provided with high-carbohydrate control food items (66 g of commercial cookies; 320 kcal, 18 g fat, 3.9 g protein, 1.2 g total dietary fiber and 0.79 mg α-tocopherol) that had a similar number of calories as 56 g of almonds (independent analyses indicates that they contain 340 kcal, 30 g fat, 12 g protein, 6.2 g total dietary fiber, and 14 mg α-tocopherol). All of the subjects were able to determine the frequency of ingestion per day as desired, if they keep the guidelines for their groups. Participants were instructed to maintain their habitual dietary intake and usual level of physical activity and avoid consuming any additional nuts or nut products throughout the study. Participants, care providers, and analysts for dietary record were not blinded because of obvious differences between treatments, whereas personnel who were in charge of assessing outcomes and data management were blinded.

Compliance and dietary assessment
---------------------------------

Compliance was measured by self-report. A consumption log sheet was provided for participants to keep a record of their almond or cookies consumption. On every Monday, subjects reported to care providers, trained registered dietitians using text message how many packages they did not consume during previous week. Good compliance was defined as \> 80% adherence to the treatment. 80% compliance was defined as intake of almond or cookies over 90 times during 16 weeks (112 days). The three-day diet records, including two consecutive weekdays and one weekend day, were done once before the trial and twice during the trial. A registered dietitian provided detailed instructions of how to fill out a diet record and report their diet by taking pictures and sending these via text messages. All dietary records were analyzed to provide an estimation of the daily average energy and nutrient intake using CAN-Pro 4.0 software (Korean Nutrition Society, Seoul, Korea).

Measurements
------------

All measurements were conducted with participants going barefoot and wearing light clothing for the baseline (week 0) and main-trial days (weeks 8 and 16). Body composition including body fat percentages was assessed through multi-frequency whole-body bioimpedance measurement using InBody 620 (Biospace Co., Ltd, Seoul, Korea). The results included body composition analysis (total body water, protein, and body fat mass), muscle-fat analysis (body weight, skeletal muscle mass, and fat free mass), obesity analysis (body fat percentage, BMI (calculated as weight (kg) divided by height in meters (m) squared)).

For measuring blood lipid profiles, after a 12-hour fast, blood samples were taken at the baseline (week 0) and at weeks 8 and 16 by standard venipuncture. Blood was centrifuged at 3,000 rpm for 15 min at 4℃. Aliquots of serum were prepared and stored at −80℃ for following biochemical measurements. The serum total cholesterol and triglycerides levels were measured by the enzymatic-colorimetric method using a Cobas 8000 c702 chemistry analyzer (Roche Diagnostics; Mannheim, Germany). HDL cholesterol and LDL cholesterol levels were determined via homogeneous enzymatic colorimetry. Non-HDL cholesterol levels were calculated from the total cholesterol and HDL cholesterol using the following formula: Non-HDL cholesterol (mg/dL) = total cholesterol - HDL cholesterol \[[@B13]\].

Waist and hip circumference measurements were measured by trained technical staff using a measuring tape (SECA-201, SECA Ltd., Hamburg, Germany). Waist circumferences were obtained at the mid-point between the lowest rib and the iliac crest to the nearest 0.1 cm after inhalation and exhalation. Hip circumferences were rounded to the nearest 0.1 cm at the widest part between the waist and knees. Weight while fasting was measured and rounded to the nearest 0.1 kg, and height was rounded to the nearest 0.1 cm using a stadiometer (BSM330, Biospace Co., Ltd, Seoul, Korea). Blood pressure was measured on the right arm using an up-load blood pressure monitor (BPBIO320S, Biospace Co., Ltd, Seoul, Korea) with participants in a comfortably seated position after at least a five-minute rest.

Serum Interleukin-6 (IL-6) was measured using an enzyme immunometric assay kit (ADI-900-033, Enzo Life Science, Farmingdale, NY, USA). Serum malondialchehyche (MDA) and oxidized LDL-C (cholesterol) were measured using commercially available kits, a human MDA ELISA kit (MBS724277, MyBioSource, San Diego, CA , USA) and oxidized LDL ELISA kit (10-1143-01, Mercodia AB, Uppsala, Sweden) with an Epoch microplate spectrophotometer (BIOTEK, Inc., Winooski, VT, USA). The coefficients of variation (CV) for all measurements were less than 4%.

Statistical analysis
--------------------

The sample size was calculated based on the sample size estimation for clinical trials using OpenEpi version 3.01. Percentages of the subjects who may show the primary outcomes in the almond groups and snack group were set at 25 and 5%, respectively. In total, 45 subjects were required in each group to provide over 80% power. The significance of the differences between the baseline (week 0) and main-trial periods (weeks 8 and 16) with different interventions was assessed using the repeated measures analysis of variance (RMANOVA) with Duncan multi-comparison, and the model assumptions were checked. Differences in baseline and Δ (changes from the baseline at weeks 8 or 16) among the three groups were detected using one-way ANOVA. All data were expressed as means with standard deviations unless otherwise specified. All statistical analyses were performed using of SAS (version 9.3; SAS Institute, Cary, NC).

RESULTS
=======

Basic characteristics, compliance, and dietary analyses
-------------------------------------------------------

In total, 169 (n = 58 for PM; 55 for SN; and 56 for CL) out of the 227 participants completed the study between June 2014 and June 2015. Fifty-eight participants dropped out due to schedule conflict, poor compliance, nausea and stomach pain, traveling, and pregnancy ([Fig. 1](#F1){ref-type="fig"}). The basic characteristics of the participants are presented in [Table 1](#T1){ref-type="table"}. Age, BMI and blood lipid profiles at baseline indicated that the subjects were healthy and young. The results of the dietary analyses ([Table 2](#T2){ref-type="table"}) showed that at weeks 8 and 16, the carbohydrate intake of the PM and SN groups was lower than that of the CL group, while the intake of vegetable fat, vegetable protein, fiber, monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA) of the PM and SN groups was significantly higher than that of the CL group.

Changes from the baseline in body composition
---------------------------------------------

Changes from baseline in body composition including total body protein, body water, body fat mass, skeletal muscle mass, and visceral fat levels are presented in [Table 3(A)](#T3){ref-type="table"}. Body weight changes from the baseline did not differ significantly for each time point among the three groups, whereas significant intervention effect was observed for changes of body fat mass (*P* = 0.025, RMANOVA) as results with one-way ANOVA revealed that body fat mass of PM group was decreased compared to CL at both weeks 8 and 16. In addition, body fat percentages in both almond groups were significantly reduced compared to the control group at week 16 using one-way ANOVA and significant interaction effect (*P* = 0.032, RMANOVA) was also observed. The visceral fat level significantly decreased in the PM group compared to the control group at both 8 and 16 weeks. In summary, consuming almond as a preload before meals reduced body fat mass, body fat percentages, and visceral obesity without reducing body weight.

Changes from the baseline in blood biochemistries
-------------------------------------------------

Blood biochemistries including lipid profiles, inflammation and anti-oxidants markers were presented in [Table 3(B)](#T3){ref-type="table"}. At baseline, CL group showed lower levels of triglycerides, LDL, and non-HDL cholesterol when compared to the PM and SN groups. Total blood cholesterol levels were significantly reduced in SN group compared to CL at week 8, not at week 16 due to the great reduction of cholesterol levels in the CL group. SN group showed significantly greater reductions of LDL cholesterol levels at week 16 than the CL and PM groups using one-way ANOVA. These results suggest that consuming almonds as a daily snack may reduce total cholesterol and LDL cholesterol levels. However, changes in blood HDL cholesterol levels were not observed throughout the trial. Due to the great reduction in the total cholesterol for the almond groups, a significant decrease in non-HDL cholesterol was observed in the SN group at both weeks 8 and 16 compared with the CL. Changes in the blood triglycerides levels did not significantly differ among the three groups based on the RMANOVA. There were significant intervention effects in changes of total cholesterol (*P* = 0.043), LDL cholesterol (*P* = 0.011), and non-HDL cholesterol (*P* = 0.013). Most of the blood chemistries also showed significant time effects as well, whereas there was no interaction between time and intervention. None of the changes in the oxidative and inflammation indicators were not significantly different among groups.

DISCUSSION
==========

Our results indicate that the daily consumption of almonds (56 g) as a snack had positive effects on blood lipid profiles, including decreased non-HDL cholesterol, LDL cholesterol, and total cholesterol levels. In addition, it was found that consuming almonds as a preload before a meal reduced body fat mass, visceral fat level, and body fat percentage. These results show that young free-living adults who do not have any clinical manifestations, such as hyperlipidemia or obesity might also obtain positive effects from the daily consumption of almonds.

One finding in the current study was that consuming almonds each day affected body fat mass and percentage without changing body weight significantly. In particular, the subjects in the PM group experienced decreased visceral fat levels, which measure the amount of fat in surrounding organs. The visceral fat cross-sectional area can be measured only by computed tomography (CT) scan. Indices for visceral fat level by bioelectrical impedance analysis (BIA) is an estimate based on the regression equation of visceral fat cross-sectional area measure by CT \[[@B14]\]. Visceral fat is potentially lipolytic; its lipotoxicity brings hepatic insulin resistance and affects insulin metabolism, which causes hyperinsulinemia, peripheral insulin resistance, and diabetes mellitus \[[@B15]\]. This finding is supported by the study done by Salas-Salvado et al. \[[@B16]\], which claimed that a diet of mixed nuts helped their subjects decrease their central adiposity or metabolic syndrome without changing their body weight. In addition, one cross-sectional study conducted among elderly subjects with high cardiovascular risk living in a Mediterranean country examined the inverse relationship between central adiposity and nut consumption \[[@B17]\]. The results of a 10-week crossover study demonstrated that when subjects consumed a 56 g of almonds each day, they compensated for the energy provided by the almonds and reduced their food intake from other sources \[[@B11]\]. The effect on visceral body fat among the subjects in the PM group might suggest that almond consumption as a preload before the meal may be related with the insulin metabolism, which could be a topic of further studies, because body fat reduction in the abdominal region facilitates glycemic control \[[@B18]\].

Other nuts have also been shown to have cardioprotective effects, especially in lowering serum lipids. The results of a Bayesian meta-analysis indicated that hazelnut-enriched diet is associated with a decrease of total and LDL cholesterols, while HDL cholesterol, triglycerides unchanged \[[@B19]\]. A recent meta-analysis of 27 randomized controlled trials intervening almonds by Musa-Veloso et al. \[[@B20]\] indicated that almond consumption was associated with a significant reduction in total and cholesterols, triglycerides, and it had no effects on HDL cholesterol. This tendency appears to be greater in hyperlipidemic patients \[[@B7][@B8][@B21]\]. Our participants, especially those in the SN group, experienced decreased non-HDL, LDL, and total cholesterols compared with those in the CL group which were consistent with previous studies which reported lipid-improving effects of almond consumption among normolipidemic patients \[[@B7][@B22]\]. The fatty acid profiles (rich in oleic and linoleic acids \[[@B23]\]) and plenty amount of protein in almonds might change the fatty acid profile and protein contents of the habitual Korean diet, which contains a large amount of carbohydrates and saturated fat \[[@B24]\]. When saturated fat was replaced by unsaturated fat, an LDL cholesterol-lowering effect was observed in several previous studies \[[@B25][@B26][@B27]\]. In addition, when people have replaced the carbohydrate in their diet with protein, both normolipidemic \[[@B28]\] and hypercholesterolemic \[[@B29]\] subjects showed beneficial effects on LDL cholesterol levels.

In previous studies, almonds were mostly added to snack foods such as cereals or muffins \[[@B7][@B8]\]. The lipid-lowering effects of almond in our study were consistent with previous studies that having almond as a snack decreases LDL cholesterol \[[@B4][@B30]\]. However, LDL cholesterol level of PM group was not significantly decreased compared with the control group. As Tan and Mattes reported \[[@B12]\], consuming almonds with meals did not have significant effects on lipid profiles. Since the effects of consuming almond as a preload have not been frequently investigated, these results suggest that potential different lipid-improving effects of almond intake based on the timing of consumption during a day. Future studies would be needed to elucidate the mechanism of how the timing of almond consumption influence lipid profiles.

One possibility for why the timing of almond consumption affected the body fat composition and lipid profiles of young adults differently might be related to the fluctuation of blood glucose concentration after meals or snacks compared with the effect of the control food. One previous study suggested that the ingestion of 28 g of almonds before a high-starch meal lowered postprandial glycemia by 30% in individuals with type 2 diabetes \[[@B31]\]. Even though we did not measure any parameters for glucose metabolism, almonds may act as a lower-glycemic index (GI) food compared with the control food. Consuming snacks such as cookies and candy that contain a high amount of glucose significantly increases the glucose and insulin levels in the blood. Blood glucose levels rapidly drop due to excessively increased insulin secretion, and the individual feels hungry again \[[@B32]\]. However, the intake of low-GI food helps the body digest the food more slowly, which generates lower glycemic and insulinemic responses, resulting in longer satiety and lower food intake. In other words, low-GI diets metabolically result in lower diabetes incidence and heart disease risk by decreasing postprandial glucose excursions \[[@B33]\]. Almond intake as a preload may decrease the consumption of habitual high-carbohydrate meals, and snacking on almonds between meals may affect the blood glucose and lipid metabolism.

Design of the current study has several strengths: a robust sample size, sufficient study duration, and comparison between almond and control food consumption. In addition to providing standard amounts of almonds, our subjects were healthy free-living young adults whose results are applicable to ordinary living situations. However, there are still several limitations to the study. Iso-caloric food contains high percentages of carbohydrates compared with almonds, which means it does not match the macronutrient composition of almonds. Additionally, the nutrients and bioactive substances generated from almonds were substituted with carbohydrate. Another limitation would be that body composition has not been carried out using dual-energy X-ray absorptiometry, or other imaging techniques (CT, magnetic resonance imaging). Further studies providing a control food item with matched macronutrient and fatty acid composition are needed.

In conclusion, regular almond consumption may help improve serum lipid profiles. Snacking almonds between meals may be more effective for improving lipid profile. Consuming almonds before meals may lower the visceral fat level and body fat mass and percentages without changing the body weight compared with iso-caloric high-carbohydrate cookies. Since the timing of almond consumption seems to be crucial regarding its effects, further study on glucose metabolism after almond consumption would provide important information.
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The following abbreviations are used in this manuscript:

DV

:   daily value

LDL cholesterol

:   low-density lipoprotein cholesterol

HDL cholesterol

:   high-density lipoprotein cholesterol

PM

:   pre-meal almond group

SN

:   snack almond group

CL

:   control group

BMI

:   body mass index

SFA

:   saturated fatty acid

MUFA

:   Monounsaturated fatty acid

PUFA

:   Polyunsaturated fatty acid

BIA

:   bioelectrical impedance analysis

CT

:   computed tomography

GI

:   glycemic index

![Flow chart of the study. PM, pre-meal almond group; SN, snack almond group; CL, control group.](nrp-11-479-g001){#F1}

###### Baseline characteristics of participants

![](nrp-11-479-i001)

^1)^Values are means ± SD.

^2)^Indicator generated from bioimpedance analysis based on the estimated amount of fat surrounding internal organs in the abdomen \[normal range: 1\~9\].

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IL, Interleukin; MDA, malondialchehyche.

###### Dietary assessment at baseline, weeks 8 and 16 of the control, pre-meal almond, snack almond interventions.

![](nrp-11-479-i002)

^1)^Values are means ± SD.

^2)^PM, pre-meal almond group; SN, snack almond group; CL, control group; SFA, saturated fatty acid; MUFA, Monounsaturated fatty acid; PUFA, Polyunsaturated fatty acid.

^3)^The different letters (a, b, and c) within a row indicate significant differences (*P* \< 0.05) determined by Duncan\'s multiple range test.

###### Changes from baseline in body composition (A) and blood biochemistries (B)

![](nrp-11-479-i003)

^1)^PM, pre-meal almond group; SN, snack almond group; CL, control group; BMI, Body Mass Index.

^2)^Indicator generated from bioimpedance analysis based on the estimated amount of fat surrounding internal organs in the abdomen \[normal range: 1\~9\].

^3)^ANOVA for repeated measures.

^4)^Between-group comparisons at the same time point were conducted using one-way ANOVA. The different letters (a, b) within a column indicate significant differences (*P* \< 0.05) determined by Duncan\'s multiple range test.

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IL, Interleukin; MDA, malondialchehyche.
